Aladdin Healthcare Technologies : Half-Year Financial Report 2020

Half-Year Financial Report 2020

Aladdin Healthcare Technologies SE

These interim financial statements and the management report of the Company have not been

reviewed by an auditor.

Table of contents
Foreword by the Managing Director ..........................................................................	4
The share........................................................................................................................	6
Share analysis ...............................................................................................................	6
Investor Relations .........................................................................................................	6
Interim Management Report for the Period 1 January to 30 June 2020 ...............	7
I.	Information about the Group.........................................................................................	7
1.	Composition and structure of the company...............................................................................	7
2.	Business model .................................................................................................................................	7
3.	Strategic goals ...................................................................................................................................	7
4.	Research and development ............................................................................................................	8
II.	Economic report...............................................................................................................	8
1.	Business performance.....................................................................................................................	8
2.	Net assets, financial position and results of operations ......................................................	10
III.	Report on future development and on opportunities and risks.........................	12
1.	Forecast report ................................................................................................................................	12
2.	Risk management system and internal controls.....................................................................	13

3.Internal control system and risk management system with regard to the group

accounting process ....................................................................................................................................	14
IV.	Corporate Governance Report .....................................................................	14
1.	Corporate Governance Code........................................................................................................	14
2.	Remuneration report ......................................................................................................................	15
3.	Takeover-relevantinformation.....................................................................................................	15
Consolidated balance sheet as at 30 June 2020 ....................................................	20
Consolidated Income Statement for the Period 1 January to 30 June 2020......	21
Consolidated statement of comprehensive income for the period 1 January to
30 June 2020 ................................................................................................................	22
Consolidated Statement of Changes in Equity for the period 1 January to 30
June 2020 .....................................................................................................................	23
Consolidated Cash Flow Statement for the Period 1 January to 30 June 2020 24
Notes to the consolidated financial statements (condensed) as at 30 June 2020
.......................................................................................................................................	25
I.	PRELIMINARY REMARKS AND BASIS OF PREPARATION ................................	25
II.	CONSOLIDATION AND ACCOUNTING RULES.......................................................	26
		2

III.	NOTES TO THE ITEMS OF THE CONSOLIDATED BALANCE SHEET AND
CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME .........................................................	38
IV.	OTHER DISCLOSURES AND EXPLANATIONS.......................................................	42
Responsibility statement by the legal representatives.........................................	48

3

Foreword by the Managing Director

Dear Shareholders,

With the publication of the report for the first half of 2020, I would like to take the opportunity to inform you about both the progress and the positioning of the business.

Highlights in the first six months of the current financial year include:

• We have developed a prototype for the early diagnosis of Alzheimer's disease based on blood test results. The AI diagnosis is based on a non-invasive blood test that can provide an instant diagnosis for health screening of several age-related diseases. We have achieved 85% accuracy in diagnosing Alzheimer's disease with our AI model based on blood test results. These diagnoses are now being validated through our extensive and industry-leading hospital network.
• The company has appointed Professor David C. Rubinsztein as Chief Scientific Advisor. David is Deputy Director of the Cambridge Institute of Medical Research, Professor of Molecular Neurogenetics at the University of Cambridge and Professor at the UK Dementia Research Institute. His research interests are in autophagy and neurodegeneration. He is a Fellow of the Royal Society and the Academy of Medical Sciences. David is a highly cited researcher by Clarivate Analytics and Thomson Reuters. He has published more than 390 papers, including studies in well-known international journals such as Nature and Cell, with more than 75,000 Google Scholar citations.
• Aladdin has developed a Health Risk Assessment Tool (HRA) as a web and mobile application to manage COVID-19 risk assessment for global use. The HRA tool combines both artificial intelligence (AI) and augmented reality (AR) to open up new possibilities in COVID-19 risk management for businesses and individuals. Aladdin will initially roll out the technology in India. It is expected that the tool will be available in the market by the end of the second quarter of 2020 and will then be rolled out in other countries. Specifically, the AI application provides users with a real-time risk assessment of individuals infected with the coronavirus. In addition, the application can take further steps in their treatment. For example, it shows whether doctors are available for a video consultation and the nearest available hospital for treatment. At the same time, the AI suggests suitable further treatment measures and gives lifestyle tips. Aladdin has long been active in the important Indian market. Together with the OurHealthMate (OHM) medical platform, Aladdin has already built a diabetes and cardiovascular risk prediction tool in India. In addition, OHM will also integrate the risk assessment platform into its ecosystem, enabling Aladdin's application to be used by more than 2,000 healthcare partners. These include large hospital operators and health insurers.

4

• The Company had decided on 6 April 2020 that it would carry out the capital increase to the extent that new shares were subscribed for in the subscription offer (including oversubscriptions by existing shareholders). To this extent, the Company issued a total of 8,238 new shares and the share capital of the Company was increased by EUR 8,238.00 from the current EUR 11,450,000.00 to EUR 11,458,238. Shareholders who subscribed or oversubscribed more than five new shares in the subscription offer will receive 2 bonus shares for every 5 new shares subscribed.

We have built an AI and data science development team from Europe, China and India. These individuals bring unparalleled healthcare networks and partners that give Aladdin credibility in the healthcare industry. As demonstrated by other healthcare technology companies, the successful completion of an 'alpha product' leads to a dramatic increase in enterprise value, which Aladdin aims to achieve in the second half of 2020 and into 2021.

Berlin, May 2021

Wade Menpes-Smith

Managing Director

5